FDA Overhauls Its Purple Book
Searchable Biologics Database Is Welcomed By Biosimilars Industry
Executive Summary
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
You may also be interested in...
Purple Book Changes May Not Go Far Enough
Despite new requirements to include details of biologic exclusivity and intellectual property in the FDA’s Purple Book that come into effect on 25 June, experts believe information gaps for biosimilars developers may still exist.
FDA Updates ‘Purple Book’ Database
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.
US Marks Biologics Transition Day
Sanofi’s Lantus stands alone as the only insulin product still listed in the ‘Orange Book’ post-transition because it is referenced in Mylan/Biocon’s pending 505(b)(2) application for insulin glargine; the FDA said it stands ready to review biosimilar and interchangeable applications that reference the newly ‘deemed’ biologic products.